Pinnacle Wealth Planning Services Inc. lessened its holdings in shares of Danaher Co. (NYSE:DHR – Free Report) by 29.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,884 shares of the conglomerate’s stock after selling 1,183 shares during the period. Pinnacle Wealth Planning Services Inc.’s holdings in Danaher were worth $662,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently made changes to their positions in DHR. Kovack Advisors Inc. boosted its holdings in Danaher by 3.4% in the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the last quarter. Gilbert & Cook Inc. raised its holdings in shares of Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after buying an additional 42 shares during the last quarter. Grimes & Company Inc. raised its holdings in Danaher by 0.6% during the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock worth $1,696,000 after purchasing an additional 43 shares in the last quarter. Harbour Investments Inc. increased its holdings in Danaher by 3.0% in the third quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after buying an additional 45 shares in the last quarter. Finally, Dakota Community Bank & Trust NA increased its holdings in Danaher by 16.4% in the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock valued at $73,000 after buying an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Insider Buying and Selling
In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on DHR
Danaher Stock Performance
Shares of NYSE:DHR opened at $210.97 on Thursday. Danaher Co. has a one year low of $196.80 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The company has a market cap of $150.78 billion, a P/E ratio of 39.96, a PEG ratio of 2.66 and a beta of 0.82. The business’s 50-day simple moving average is $223.22 and its 200 day simple moving average is $243.63.
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the business earned $2.09 earnings per share. On average, sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is an increase from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is currently 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Growth Stocks: What They Are, What They Are Not
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- What to Know About Investing in Penny Stocks
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Compound Interest and Why It Matters When Investing
- Is Advanced Micro Devices Stock Slide Over?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.